Outlook Therapeutics to Present at EURETINA Innovation Spotlight
ByAinvest
Wednesday, Sep 3, 2025 8:36 am ET1min read
OTLK--
The presentation will focus on the company's efforts to optimize the standard of care for bevacizumab in the treatment of retina diseases. Outlook Therapeutics has received marketing authorization for LYTENAVA™ (bevacizumab gamma) in Europe for the treatment of wet AMD. The company's ONS-5010/LYTENAVA™ (bevacizumab-vikg) is currently under investigation in the United States. Despite the FDA's Complete Response Letter (CRL) for ONS-5010/LYTENAVA™ due to a lack of substantial evidence of effectiveness, the company is committed to addressing the regulatory concerns and advancing its therapeutic potential.
References:
[1] https://www.stocktitan.net/news/OTLK/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-keyraxjtd89i.html
[2] https://www.stocktitan.net/news/OTLK/outlook-therapeutics-provides-regulatory-update-on-u-s-food-and-drug-nbyjrm2bh7f4.html
Outlook Therapeutics will present at the 2025 EURETINA Innovation Spotlight on September 3, 2025, in Paris. Bob Jahr, CEO, will present "Optimising the treatment of retinal disease" in the VEGF Related and Other Retinal Indications session. Outlook Therapeutics focuses on optimizing bevacizumab treatment for retina diseases and has received marketing authorization for LYTENAVA (bevacizumab gamma) in Europe for wet AMD.
Outlook Therapeutics (NASDAQ: OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, will present at the 2025 EURETINA Innovation Spotlight. The presentation, titled "Optimising the treatment of retinal disease," will be delivered by CEO Bob Jahr on September 3, 2025, at 16:10 PM CEST / 10:10 AM EDT in Paris, France.The presentation will focus on the company's efforts to optimize the standard of care for bevacizumab in the treatment of retina diseases. Outlook Therapeutics has received marketing authorization for LYTENAVA™ (bevacizumab gamma) in Europe for the treatment of wet AMD. The company's ONS-5010/LYTENAVA™ (bevacizumab-vikg) is currently under investigation in the United States. Despite the FDA's Complete Response Letter (CRL) for ONS-5010/LYTENAVA™ due to a lack of substantial evidence of effectiveness, the company is committed to addressing the regulatory concerns and advancing its therapeutic potential.
References:
[1] https://www.stocktitan.net/news/OTLK/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-keyraxjtd89i.html
[2] https://www.stocktitan.net/news/OTLK/outlook-therapeutics-provides-regulatory-update-on-u-s-food-and-drug-nbyjrm2bh7f4.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet